Case Report

Rare Case of Fatal Yellow Fever Vaccine-associated Viscerotropic Disease

Authors: CPT Gregg Gerasimon, MD, MC, USA, MAJ Kristie Lowry, MD, MC, USA

Abstract

This report describes a case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) that occurred after vaccination in a 22-year-old female. Our patient presented with a clinical syndrome of fever, headache, nausea, and vomiting, which quickly progressed to multiorgan failure and ultimately death on hospital day 4. YEL-AVD is an extremely rare condition reported only a few times in the literature. The yellow fever vaccine is a known stimulus of systemic inflammation in the body. A mild subclinical viremia develops, which results in a persistent and robust T-helper-cell-dependent antibody response with long-lasting immune protection. The very rare patient may have an aberrant response to the 17D vaccine strain, causing the multiple organ system failure seen in YEL-AVD. Predisposing host factors that contribute to YEL-AVD are not yet known. Treatment for YEL-AVD is supportive. To the authors’ knowledge, this patient was the first to have YEL-AVD as a result of standard US military vaccination protocols.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Weir E. Yellow fever vaccination: be sure the patient needs it. CMAJ 2001;165:941.
 
2. Lang J, Zuckerman J, Clarke P, et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999;60:1045–1050.
 
3. Wilson M. Travel-related vaccines. Infect Dis Clin North Am 2001;15:231–251.
 
4. Sencer D, Langmuir A, Kokko U. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. JAMA 1966;198:671–672.
 
5. Notice to readers: fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996–2001. MMWR Wkly 2001;50:643–645.
 
6. Martin M, Tsai T, Cropp B, et al. Fever and multiple organ system failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001;358:98–104.
 
7. Levy S, Mullane K, Miller M, et al. adverse events associated with 17D-derived yellow fever vaccination: United States, 2001–2002. JAMA 2002;288:2533–2535.
 
8. Weir E, Haider S. Yellow fever: readily prevented but difficult to treat. CMAJ 2004;170:1909–1910.
 
9. Hacker U, Jelinek T, Erhardt S, et al. In vivo synthesis of tumor necrosis factor-α in healthy humans after live yellow fever vaccination. J Infect Dis 1998;177:774–778.
 
10. van der Beek M, Visser L, de Maat M. Yellow fever vaccination as a model to study the response to stimulation of the inflammation system. Vascul Pharmacol 2002;39:117–121.
 
11. Marchevsky R, Freire M, Coutinho E, et al. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 2003;316:55–63.
 
12. Reinhardt B, Jaspert R, Neidrig M, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998;56:159–167.
 
13. Vasconcelos P, Luna E, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001;358:91–97.
 
14. Galler R, Pugachev K, Santos C, et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001;290:309–319.
 
15. Verschuur M, van der Beek M, Tak H, et al. Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination. Blood Coagul Fibrinolysis 2004;15:399–404.
 
16. CDC. Questions and answers about yellow fever vaccine and recent reports of associated severe illness. Available at: http://www.cdc.gov/ncidod/dvbid/yellowfever/vaccine/qa.htm. Accessed March, 2005.
 
17. Monath T, Cetron M. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis2002;34:1369–1378.
 
18. McFarland J, Baddour L, Nelson J, et al. Imported yellow fever in a United States citizen. Clin Infect Dis 1997;25:1143–1147.
 
19. Monath T. Yellow fever. Available at: http://www.uptodate.com. Accessed March, 2005.
 
20. Arroyo J, Apperson S, Cropp C, et al. Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg 1988;38:647–650.
 
21. Chan R, Penney D, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001;358:121–122.